Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3M-RGD: Mycophenolate Mofetil + Methimazole in Newly Diagnosed Graves' Disease
NCT06068179Phase 3Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mycophenolate mofetil in Graves' disease (2 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Remission Rate at 12 months. Started Oct 2023; status: recruiting.
02
Drugs
mycophenolate mofetil
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT06068179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06068179.